- Tiziana Life Sciences has raised GBP3.8m via the issue of 2.6m unsecured convertible loan notes to investors. Proceeds would be used to fund the development of Tiziana's clinical stage assets milciclib and foralumab, meet ongoing liabilities in respect of licence agreements, and for general working capital purposes.

Story provided by